Suppr超能文献

乳腺癌中受体状态的变化。

Variation of receptor status in cancer of the breast.

作者信息

Harland R N, Barnes D M, Howell A, Ribeiro G G, Taylor J, Sellwood R A

出版信息

Br J Cancer. 1983 Apr;47(4):511-5. doi: 10.1038/bjc.1983.81.

Abstract

One hundred and nineteen patients with breast cancer had 2 or more lesions removed for oestrogen (REc) or progesterone receptor (RPc) assay, either synchronously (on 38 occasions) or after an interval (on 91 occasions). In all but 7 both receptors were assayed for each lesion. The assays did not agree on the presence or absence of REc alone, RPc alone or the combination of both receptors in 11, 13 and 16% respectively of the synchronous samples, compared with 23, 30 and 43% of the asynchronous samples. The differences between the synchronous and asynchronous samples were significant for the combined receptors (P = 0.007) but not for REc (P = 0.176) or RPc alone (P = 0.077). Variation between asynchronous biopsies was greater when the earlier lesion contained RPc (18/37 disagreed) than when it did not (8/50) disagreed, P = 0.0023). This was not true for oestrogen receptor. In those remaining receptor positive there was only a weak correlation between the first and second values (Spearman rank correlation coefficient, rho = 0.39 for REc, P less than 0.02, and 0.45 for RPc, 0.05 less than P less than 0.1). Receptor levels and receptor status may change with time. Biopsy is most appropriate at the time when systemic treatment is proposed.

摘要

119例乳腺癌患者切除了2个或更多病灶以进行雌激素(REc)或孕激素受体(RPc)检测,检测方式为同步检测(共38次)或间隔一段时间后检测(共91次)。除7例患者外,其余患者对每个病灶均检测了两种受体。对于同步样本,单独REc、单独RPc或两种受体同时存在与否的检测结果不一致的情况分别占11%、13%和16%;而异步样本中这三种情况分别占23%、30%和43%。同步样本和异步样本在联合受体检测结果上差异显著(P = 0.007),但单独REc检测(P = 0.176)和单独RPc检测(P = 0.077)结果差异不显著。当早期病灶含有RPc时,异步活检之间的差异更大(18/37不一致),而早期病灶不含RPc时差异较小(8/50不一致),P = 0.0023)。雌激素受体情况并非如此。在其余受体阳性的患者中,首次和第二次检测值之间只有微弱的相关性(Spearman等级相关系数,REc为rho = 0.39,P < 0.02;RPc为0.45,0.05 < P < 0.1)。受体水平和受体状态可能随时间变化。活检最适合在提议进行全身治疗时进行。

相似文献

1
Variation of receptor status in cancer of the breast.乳腺癌中受体状态的变化。
Br J Cancer. 1983 Apr;47(4):511-5. doi: 10.1038/bjc.1983.81.
2
The clinical value of multiple steroid receptor assays in breast cancer management.多种类固醇受体检测在乳腺癌管理中的临床价值。
Cancer. 1980 Dec 15;46(12 Suppl):2939-45. doi: 10.1002/1097-0142(19801215)46:12+<2939::aid-cncr2820461440>3.0.co;2-5.
5
Progesterone and oestrogen receptors in human breast cancer.人类乳腺癌中的孕激素和雌激素受体
Aust N Z J Med. 1978 Dec;8(6):630-8. doi: 10.1111/j.1445-5994.1978.tb04853.x.

引用本文的文献

6
Nandrolone decanoate added to tamoxifen in the treatment of advanced breast cancer.
Breast Cancer Res Treat. 1985;5(1):75-80. doi: 10.1007/BF01807653.

本文引用的文献

2
Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer.晚期乳腺癌中雌激素受体定量评估的临床意义
Cancer. 1980 Dec 15;46(12 Suppl):2889-95. doi: 10.1002/1097-0142(19801215)46:12+<2889::aid-cncr2820461430>3.0.co;2-4.
3
The value of estrogen and progesterone receptors in the treatment of breast cancer.雌激素和孕激素受体在乳腺癌治疗中的价值。
Cancer. 1980 Dec 15;46(12 Suppl):2884-8. doi: 10.1002/1097-0142(19801215)46:12+<2884::aid-cncr2820461429>3.0.co;2-u.
5
Analysis of estradiol and progesterone receptors in early and advanced breast tumors.早期和晚期乳腺肿瘤中雌二醇和孕酮受体的分析
Cancer. 1980 Dec 15;46(12 Suppl):2818-21. doi: 10.1002/1097-0142(19801215)46:12+<2818::aid-cncr2820461416>3.0.co;2-z.
6
The value of progesterone receptor assays in the management of advanced breast cancer.
Cancer. 1980 Dec 15;46(12 Suppl):2789-93. doi: 10.1002/1097-0142(19801215)46:12+<2789::aid-cncr2820461409>3.0.co;2-k.
8
Studies on estrogen receptors and regression in human breast cancer.关于人类乳腺癌中雌激素受体与消退的研究。
Cancer. 1980 Jun 15;45(12):2998-3003. doi: 10.1002/1097-0142(19800615)45:12<2998::aid-cncr2820451220>3.0.co;2-i.
9
The role of progesterone receptors in the management of advanced breast cancer.孕激素受体在晚期乳腺癌治疗中的作用。
Cancer. 1980 Jun 15;45(12):2992-7. doi: 10.1002/1097-0142(19800615)45:12<2992::aid-cncr2820451218>3.0.co;2-d.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验